title: Effect of neuropeptide Y on inflammatory paw edema in the rat: involvement of peripheral NPY Y1 and Y5 receptors and interaction with dipeptidyl-peptidase IV (CD26).
abstract: Several lines of evidence suggest that neuropeptide Y (NPY) may exert regulatory effects in local inflammatory responses. Here, we show that intraplantarly (i.pl.) applied NPY, peptide YY (PYY), and an NPY Y5 receptor-selective agonist dose-dependently potentiate concanavalin A (Con A)-induced paw edema in the rat. The NPY Y1 receptor antagonist BIBO 3304 abolishes the pro-inflammatory action of both NPY and PYY while the dipeptidyl-peptidase IV (CD26) inhibitor Ile-thiazolidide exerted synergistic and potentiating effects in vivo. Taken together, the present data reveal an NPY Y1/Y5 receptor interplay and an involvement of CD26 in the NPY-induced potentiation of paw edema in the rat.
authors.affiliation: Immunology Research Center Branislav Janković, Institute of Immunology and Virology "Torlak", Vojvode Stepe 458, 11152, Belgrade, Yugoslavia. ilijadim@EUnet.YU
authors.forename: Mirjana
authors.initials: M
authors.lastname: Dimitrijević
authors.forename: Stanislava
authors.initials: S
authors.lastname: Stanojević
authors.forename: Vesna
authors.initials: V
authors.lastname: Vujić
authors.forename: Vesna
authors.initials: V
authors.lastname: Kovacević-Jovanović
authors.forename: Annette
authors.initials: A
authors.lastname: Beck-Sickinger
authors.forename: Hans
authors.initials: H
authors.lastname: Demuth
authors.forename: Stephan
authors.initials: S
authors.lastname: von Hörsten
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D002478:Cells, Cultured; D003208:Concanavalin A / Q000494:pharmacology; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects / Q000276:immunology*; D004305:Dose-Response Relationship, Drug; D004487:Edema / Q000139:chemically induced / Q000201:enzymology / Q000276:immunology*; D006861:Hydrogen Peroxide / Q000276:immunology / Q000378:metabolism; D007249:Inflammation / Q000139:chemically induced / Q000201:enzymology / Q000276:immunology*; D007532:Isoleucine / Q000031:analogs & derivatives* / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D009478:Neuropeptide Y / Q000031:analogs & derivatives* / Q000276:immunology* / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D019894:Peptide YY / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D017476:Receptors, Neuropeptide Y / Q000819:agonists / Q000037:antagonists & inhibitors / Q000276:immunology*; D013844:Thiazoles / Q000494:pharmacology
chemical_list: D009478:Neuropeptide Y; D010446:Peptide Fragments; D017476:Receptors, Neuropeptide Y; D013844:Thiazoles; C114061:isoleucyl-thiazolidide; C062924:neuropeptide Y (13-36); C113547:neuropeptide Y (3-36); C097212:neuropeptide Y-Y1 receptor; C100568:neuropeptide Y5 receptor; D007532:Isoleucine; D019894:Peptide YY; D003208:Concanavalin A; C062259:neuropeptide Y, Leu(31)-Pro(34)-; D001120:Arginine; D006861:Hydrogen Peroxide; D018819:Dipeptidyl Peptidase 4; C117416:BIBO 3304